Modality
Gene Therapy
MOA
CGRPant
Target
APOC3
Pathway
Hedgehog
SchizophreniaPancreatic Ca
Development Pipeline
Preclinical
~Oct 2016
→ ~Jan 2018
Phase 1
Apr 2018
→ May 2025
Phase 1Current
NCT03175618
74 pts·Pancreatic Ca
2018-04→2025-05·Not yet recruiting
74 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-05-2110mo agoPh2 Data· Pancreatic Ca
Trial Timeline
Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3
P1/2
Not yet…
Catalysts
Ph2 Data
2025-05-21 · 10mo ago
Pancreatic Ca
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03175618 | Phase 1/2 | Pancreatic Ca | Not yet recr... | 74 | UPCR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-1944 | Pfizer | NDA/BLA | APOC3 | |
| Terafutibatinib | Pfizer | Phase 1/2 | CD38 | |
| Sotovorutinib | Pfizer | Approved | Aβ | |
| Doxacapivasertib | Eli Lilly | Phase 3 | APOC3 | |
| ABB-3060 | AbbVie | Phase 2 | LAG-3 | |
| AZN-6294 | AstraZeneca | Phase 2/3 | APOC3 | |
| Zanutinib | Bristol-Myers Squibb | Phase 2/3 | APOC3 | |
| GIL-6239 | Gilead Sciences | Phase 2 | TNFα | |
| Tezecilimab | Regeneron | Approved | IL-23 | |
| ALN-5628 | Alnylam | Phase 1/2 | APOC3 |